(R)-Buciclovir
(R)-Buciclovir is an orally active acyclic guanosine analog anti-herpetic agent that, following selective phosphorylation by HSV thymidine kinase, generates a triphosphate metabolite that inhibits viral DNA polymerase and DNA synthesis, thereby exerting anti-HSV activity. (R)-Buciclovir can be used for research on herpes simplex virus infection and genital herpes.
For research use only. We do not sell to patients.
- CAS No.: 86304-28-1
- Formula: C9H13N5O3
- Molecular Weight:239.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
|
HSV-1 1.0 μM (IC50, HEL cells) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | IC50 |
2.1 μM
|
Inhibition of HSV-1 C-42 plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-1 C-42 plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
230.0 μM
|
Inhibition of acyclovir-resistant HSV-1 C-42 Acvr plaque formation in Vero cells by plaque reduction assay.
Inhibition of acyclovir-resistant HSV-1 C-42 Acvr plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
1.2 μM
|
Inhibition of HSV-1 7935-72 plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-1 7935-72 plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
7.0 μM
|
Inhibition of HSV-1 KJ502 plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-1 KJ502 plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
6.8 μM
|
Inhibition of HSV-1 C1(101) plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-1 C1(101) plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
5.0 μM
|
Inhibition of HSV-1 Sc16 plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-1 Sc16 plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
4.0 μM
|
Inhibition of HSV-2 91075 plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-2 91075 plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
≥ 250 μM
|
Inhibition of acyclovir-resistant HSV-2 91075 Acvr plaque formation in Vero cells by plaque reduction assay.
Inhibition of acyclovir-resistant HSV-2 91075 Acvr plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
11.0 μM
|
Inhibition of HSV-2 B4327 plaque formation in Vero cells by plaque reduction assay.
Inhibition of HSV-2 B4327 plaque formation in Vero cells by plaque reduction assay.
|
3024562 |
| HEL | IC50 |
1.0 μM
|
Inhibition of HSV-1 C-42 plaque formation in HEL cells by plaque reduction assay.
Inhibition of HSV-1 C-42 plaque formation in HEL cells by plaque reduction assay.
|
3024562 |
| HEL | IC50 |
5.9 μM
|
Inhibition of HSV-2 91075 plaque formation in HEL cells by plaque reduction assay.
Inhibition of HSV-2 91075 plaque formation in HEL cells by plaque reduction assay.
|
3024562 |
| Vero | IC50 |
2300 μM
|
Inhibition of cell proliferation in Vero cells after 48 h incubation by cell growth inhibition assay using a cell counter.
Inhibition of cell proliferation in Vero cells after 48 h incubation by cell growth inhibition assay using a cell counter.
|
3024562 |
| HEL | IC50 |
170 μM
|
Inhibition of cell proliferation in HEL cells after 48 h incubation by cell growth inhibition assay using a cell counter.
Inhibition of cell proliferation in HEL cells after 48 h incubation by cell growth inhibition assay using a cell counter.
|
3024562 |
In Vitro
(R)-Buciclovir (compound BCV) effectively inhibits HSV-1 and HSV-2 replication in in vitro cell culture experiments[1].
(R)-Buciclovir (5-500 μM) affects cell sensitivity to (R)-Buciclovir through the herpes simplex virus type 1 (HSV-1) DNA polymerase gene[4].
(R)-Buciclovir (compound BCV) inhibits plaque formation by HSV-1 and HSV-2, with its inhibitory potency varying depending on the virus strain and host cell type. The highest activity is observed against HSV-1 C-42 in HEL cells, with an IC50 of 1.0 μM[2].
(R)-Buciclovir (500-1000 μM) induces a concentration-dependent clastogenic effect in cultured human lymphocytes in vitro, producing almost exclusively chromatid breaks, with abnormal metaphase figures reaching up to 44.0% at 1000 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
(R)-Buciclovir (5-20% wt/wt; topical application; 4 times daily for 5 days) reduces vaginal HSV-2 replication and decreases mortality in intravaginally infected NMRI mice, whereas systemic intraperitoneal administration of (R)-Buciclovir (37.5 mg/kg every 6 h for 5 days) has no effect on mortality or mean day of death, and systemic oral administration of (R)-Buciclovir (200-400 mg/kg daily; continuous dosing) fails to produce a statistically significant reduction in cumulative mortality across different HSV-2 strains and does not prevent viral spread to the nervous system[1].
(R)-Buciclovir (compound BCV) (5-20 mg/kg per day; i.p.; twice daily; for 5 consecutive days) provides complete survival protection in mice with systemic HSV-1 C-42 infection at daily doses of 10 and 20 mg/kg[2].
(R)-Buciclovir (10-400 mg/kg per day; i.p. or p.o.) significantly reduces the mortality rate and prolongs the average survival time of mice systemically infected with HSV-2 91075[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dunkin-Hartley (Young, female, 225 to 250 g, intravaginal inoculation of HSV-2 strain MS at 7×104 PFU following mild vaginal mucosa injury)[1]
-
Dosage:5% wt/wt topical cream; 10% wt/wt topical cream; 200 mg/kg per day (subcutaneous); 300 mg/kg per day (subcutaneous); 400 mg/kg per day (subcutaneous)
-
Administration:topical; four times daily; 5 days (starting at 1 h, 24 h, 48 h, or 72 h post-infection); subcutaneous; twice daily; 5 days (starting at 1 h, 24 h, or 72 h post-infection)
-
Result:Reduced cumulative lesion score by 73% with topical 5% (R)-buciclovir treatment starting 1 h post-infection.
Reduced mean intravaginal titers on days 1 to 3 post-infection by 99% or more with topical 10% (R)-buciclovir treatment starting 1 h post-infection, with titers of 1.30 log10 PFU/mL at 24 h post-infection, 2.54 log10 PFU/mL at 48 h post-infection, and 1.70 log10 PFU/mL at 72 h post-infection, and a cumulative lesion score of 6.3.
Recorded a cumulative lesion score of 35.8 with topical 10% (R)-buciclovir treatment starting 24 h post-infection, with mean intravaginal titers of 4.90 log10 PFU/mL at 24 h post-infection, 3.20 log10 PFU/mL at 48 h post-infection, and 2.75 log10 PFU/mL at 72 h post-infection.
Recorded a cumulative lesion score of 34.2 with topical 10% (R)-buciclovir treatment starting 48 h post-infection, with mean intravaginal titers of 4.69 log10 PFU/mL at 24 h post-infection, 4.73 log10 PFU/mL at 48 h post-infection, and 2.79 log10 PFU/mL at 72 h post-infection.
Recorded a cumulative lesion score of 40.1 with topical 10% (R)-buciclovir treatment starting 72 h post-infection, with mean intravaginal titers of 5.13 log10 PFU/mL at 24 h post-infection, 4.67 log10 PFU/mL at 48 h post-infection, and 4.10 log10 PFU/mL at 72 h post-infection.
Reduced cumulative lesion score by 48% (mean cumulative lesion score 25.0) with subcutaneous 200 mg/kg per day (R)-buciclovir treatment starting 1 h post-infection.
Reduced cumulative lesion score by 69% (mean cumulative lesion score 15.0) with subcutaneous 300 mg/kg per day (R)-buciclovir treatment starting 1 h post-infection.
Recorded a cumulative lesion score of 12.1 with subcutaneous 400 mg/kg per day (R)-buciclovir treatment starting 24 h post-infection.
Produced a 48% reduction in cumulative lesion score (17.8) with subcutaneous 400 mg/kg per day (R)-buciclovir treatment starting 72 h post-infection, with no animals progressing to the most severe disease stage 5, and only 1 of 8 animals progressing to stage 4.
Showed no effect on measured intravaginal virus titers with subcutaneous (R)-buciclovir treatments.
-
Animal Model:NMRI (Female, 15 g, intravaginal inoculation with 7×104 PFU of HSV-2 strain MS or 2×104 PFU of HSV-2 strain 91075)[1]
-
Dosage:5% wt/wt topical cream; 10% wt/wt topical cream; 20% wt/wt topical cream; 37.5 mg/kg (intraperitoneal, every 6 h); 200 mg/kg per day (oral); 400 mg/kg per day (oral)
-
Administration:topical; four times daily; 5 days (starting 1 h post-infection); intraperitoneal; every 6 h; 5 days (starting 1 h post-infection); oral; continuous; throughout the experiment after infection
-
Result:Resulted in 8 deaths out of 15 mice (53% mortality) with a mean day of death of 9.5 days for HSV-2 strain MS infection with topical 5% (R)-Buciclovir treatment.
Resulted in 4 out of 15 deaths (27% mortality) with a mean day of death of 12.3 days for HSV-2 strain MS infection with topical 10% (R)-Buciclovir treatment.
Resulted in 1 out of 15 deaths (7% mortality) for HSV-2 strain MS infection with topical 20% (R)-Buciclovir treatment.
Resulted in 8 out of 15 deaths (53% mortality) with a mean day of death of 9.8 days for HSV-2 strain 91075 infection with topical 10% (R)-Buciclovir treatment.
Resulted in 4 out of 15 deaths (27% mortality) with a mean day of death of 10.8 days for HSV-2 strain 91075 infection with topical 20% (R)-Buciclovir treatment.
Reduced the mean genital virus titers from days 1 to 3 post-infection by 98% or more with topical (R)-Buciclovir treatment starting 1 h post-infection.
Showed no effect on cumulative mortality, mean day of death, or vaginal virus replication with intraperitoneal 150 mg/kg per day (R)-Buciclovir treatment.
Resulted in 15 out of 15 deaths (100% mortality) with a mean day of death of 8.3 days for HSV-2 strain MS infection with oral (R)-Buciclovir at 1 mg/mL.
Resulted in 12 out of 15 deaths (80% mortality) with a mean day of death of 8.8 days for HSV-2 strain MS infection with oral (R)-Buciclovir at 2 mg/mL.
Resulted in 12 out of 15 deaths (80% mortality) with a mean day of death of 7.3 days for HSV-2 strain 91075 infection with oral (R)-Buciclovir at 1 mg/mL.
Resulted in 12 out of 15 deaths (80% mortality) with a mean day of death of 9.0 days for HSV-2 strain 91075 infection with oral (R)-Buciclovir at 2 mg/mL.
Produced no statistically significant effects on the cumulative mortality rate for any oral (R)-Buciclovir dose.
Failed to prevent the spread of virus to the spinal cord and brain with systemic (R)-Buciclovir administration.
-
Animal Model:NMRI mice (female, 14 to 15 g)[2]
-
Dosage:5 mg/kg per day; 10 mg/kg per day; 20 mg/kg per day
-
Administration:i.p.; twice daily; 5 consecutive days
-
Result:Recorded 5 out of 10 treated mice died, with a mean days to death of 9.2 at 5 mg/kg per day.
Recorded 0 out of 10 treated mice died at 10 mg/kg per day.
Recorded 0 out of 10 treated mice died at 20 mg/kg per day.
-
Animal Model:NMRI mice (female, 14 to 15 g)[2]
-
Dosage:10 mg/kg per day (i.p.); 25 mg/kg per day (i.p.); 50 mg/kg per day (i.p.); 400 mg/kg per day (p.o.)
-
Administration:i.p.; twice daily; 5 consecutive days; p.o. (via drinking water); 10 days
-
Result:Recorded 2 out of 10 treated mice died, with a mean days to death of 11.0 at 10 mg/kg per day i.p.
Recorded 2 out of 10 treated mice died, with a mean days to death of 13.0 at 25 mg/kg per day i.p.
Recorded 1 out of 10 treated mice died, with a mean days to death of 13.0 at 50 mg/kg per day i.p.
Recorded 3 out of 16 treated mice died, with a mean days to death of 13.7 at 400 mg/kg per day p.o.
Chemical Information
-
CAS No. 86304-28-1
-
Molecular Weight 239.24
-
Formula C9H13N5O3
-
SMILES
C(C[C@H](CO)O)N1C2=C(N=C1)C(=O)N=C(N)N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- (R)-Buciclovir
- 86304-28-1
- HSV
- DNA/RNA Synthesis
- HEL cells
- Vero cells
- herpes simplex virus infection
- herpes simplex virus type 1 thymidine kinase
- herpes simplex virus DNA polymerase
- herpes simplex virus type 2 thymidine kinase
- BHK cells
- NMRI mice
- Dunkin-Hartley guinea pigs
- human lymphocytes
- Inhibitor
- inhibitor
- inhibit